Vaccine-preventable Disease in Older Australian Adults

Background: There are limited measures of adult vaccination coverage and factors associated with adult vaccination in Australia. Methods: A systematic review and meta-analysis on influenza and pneumococcal vaccination coverage in Australian adults from 1990-2015 were conducted. Self-reported vaccination data from the 45 and Up Study, a large ongoing prospective cohort study of adults in New South Wales (Australia’s most populous state), were compared to data from the national health insurance scheme, the Medicare Benefits Schedule (MBS) and were subsequently used to investigate vaccination coverage and factors associated with vaccine receipt. A log-binomial model was used to estimate prevalence ratios, adjusted for age and other factors. Results: The systematic review identified 22 studies reporting adult influenza and/or pneumococcal vaccination coverage in Australia. Following introduction of funding, in adults aged > 65 years the summary estimates for influenza and pneumococcal vaccine coverage were 74.8% (95% CI 73.4–76.2%) and 56.0% (95% CI 53.2-58.8) respectively. Limited data for Aboriginal and Torres Strait Islander Australians was available. Linkage of the cohort data with MBS data showed overall agreement on reported influenza vaccination was 70%. Analyses of cohort participants found 67.1% (8576/12779) of those aged > 65 years had an influenza vaccination within the last year whilst 23.5% (16202/68964) reported ever receiving an adult pertussis vaccine. Factors consistently associated with receiving either vaccine were female sex (aPR influenza aPR 1.04 [95%CI 1.02-1.06], pertussis aPR 1.80 [95%CI 1.73-1.86]), non-English speaking country of birth (aPR influenza 0.88[0.83-0.94], pertussis 0.56[0.51-0.63]) and smokers (aPR influenza 0.91[0.84-0.99], pertussis 0.67[0.61-0.75). Receipt of influenza vaccine was more likely in overweight or obese individuals and those with a chronic illness but this was not the case for pertussis vaccine. Conclusion: There are limited data on Australian adult vaccination coverage. Coverage levels found for influenza and pertussis vaccines are sub-optimal and there are sub-groups who could be targeted for vaccination campaigns to improve vaccination

Emerging data inputs for infectious diseases surveillance and decision making

Infectious diseases create a significant health and social burden globally and can lead to outbreaks and epidemics. Timely surveillance for infectious diseases is required to inform both short and long term public responses and health policies. Novel data inputs for infectious disease surveillance and public health decision making are emerging, accelerated by the COVID-19 pandemic. These include the use of technology-enabled physiological measurements, crowd sourcing, field experiments, and artificial intelligence (AI). These technologies may provide benefits in relation to improved timeliness and reduced resource requirements in comparison to traditional methods. In this review paper, we describe current and emerging data inputs being used for infectious disease surveillance and summarize key benefits and limitations

Automatically applying a credibility appraisal tool to track vaccination-related communications shared on social media

Background: Tools used to appraise the credibility of health information are time-consuming to apply and require context-specific expertise, limiting their use for quickly identifying and mitigating the spread of misinformation as it emerges. Our aim was to estimate the proportion of vaccination-related posts on Twitter are likely to be misinformation, and how unevenly exposure to misinformation was distributed among Twitter users. Methods: Sampling from 144,878 vaccination-related web pages shared on Twitter between January 2017 and March 2018, we used a seven-point checklist adapted from two validated tools to appraise the credibility of a small subset of 474. These were used to train several classifiers (random forest, support vector machines, and a recurrent neural network with transfer learning), using the text from a web page to predict whether the information satisfies each of the seven criteria. Results: Applying the best performing classifier to the 144,878 web pages, we found that 14.4\% of relevant posts to text-based communications were linked to webpages of low credibility and made up 9.2\% of all potential vaccination-related exposures. However, the 100 most popular links to misinformation were potentially seen by between 2 million and 80 million Twitter users, and for a substantial sub-population of Twitter users engaging with vaccination-related information, links to misinformation appear to dominate the vaccination-related information to which they were exposed. Conclusions: We proposed a new method for automatically appraising the credibility of webpages based on a combination of validated checklist tools. The results suggest that an automatic credibility appraisal tool can be used to find populations at higher risk of exposure to misinformation or applied proactively to add friction to the sharing of low credibility vaccination information.Comment: 8 Pages, 5 Figure

Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program

Background While recommendations to vaccinate adults against pertussis exist, information on uptake for adult tetanus-diphtheria-pertussis vaccine (Tdap) among older adults is limited. Methods We used data from the 45 and Up Study, a prospective cohort of adults aged ≥45 years who completed a questionnaire between 2012 and 2014 asking about pertussis vaccination. We evaluated Tdap uptake following a program providing free vaccine for adults in contact with young children between 2009 and 2012. Results Among 91,432 adults (mean age = 66.3 years, SD = 9.6), 3.1% (n = 2823) reported receiving Tdap prior to the program. This increased seven-fold to 21.8% (n = 19898) after the program finished. Tdap coverage was almost twice as high in women compared to men and among adults more likely to be grandparents than those not. Conclusion These findings suggest that funding for a targeted program can help to substantially increase vaccination coverage as well as decrease disparities in the uptake of Tdap in different sub-groups.This study was funded by the Australian National Health and Medical Research Council (NHMRC) grant no 1048180. AD received a PhD scholarship from the NHMRC. BL, JK, EB receive fellowships from the NHMRC

Strategies to improve control of sexually transmissible infections in remote Australian Aboriginal communities: a stepped-wedge, cluster-randomised trial

BACKGROUND: Remote Australian Aboriginal communities have among the highest diagnosed rates of sexually transmissible infections (STIs) in the world. We did a trial to assess whether continuous improvement strategies related to sexual health could reduce infection rates. METHODS: In this stepped-wedge, cluster-randomised trial (STIs in remote communities: improved and enhanced primary health care [STRIVE]), we recruited primary health-care centres serving Aboriginal communities in remote areas of Australia. Communities were eligible to participate if they were classified as very remote, had a population predominantly of Aboriginal people, and only had one primary health-care centre serving the population. The health-care centres were grouped into clusters on the basis of geographical proximity to each other, population size, and Aboriginal cultural ties including language connections. Clusters were randomly assigned into three blocks (year 1, year 2, and year 3 clusters) using a computer-generated randomisation algorithm, with minimisation to balance geographical region, population size, and baseline STI testing level. Each year for 3 years, one block of clusters was transitioned into the intervention phase, while those not transitioned continued usual care (control clusters). The intervention phase comprised cycles of reviewing clinical data and modifying systems to support improved STI clinical practice. All investigators and participants were unmasked to the intervention. Primary endpoints were community prevalence and testing coverage in residents aged 16–34 years for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis . We used Poisson regression analyses on the final dataset and compared STI prevalences and testing coverage between control and intervention clusters. All analyses were by intention to treat and models were adjusted for time as an independent covariate in overall analyses. This study was registered with the Australia and New Zealand Clinical Trials Registry, ACTRN12610000358044. FINDINGS: Between April, 2010, and April, 2011, we recruited 68 primary care centres and grouped them into 24 clusters, which were randomly assigned into year 1 clusters (estimated population aged 16–34 years, n=11 286), year 2 clusters (n=10 288), or year 3 clusters (n=13 304). One primary health-care centre withdrew from the study due to restricted capacity to participate. We detected no difference in the relative prevalence of STIs between intervention and control clusters (adjusted relative risk [RR] 0·97, 95% CI 0·84–1·12; p=0·66). However, testing coverage was substantially higher in intervention clusters (22%) than in control clusters (16%; RR 1·38; 95% CI 1·15–1·65; p=0·0006). INTERPRETATION: Our intervention increased STI testing coverage but did not have an effect on prevalence. Additional interventions that will provide increased access to both testing and treatment are required to reduce persistently high prevalences of STIs in remote communities.James Ward, Rebecca J Guy, Alice R Rumbold, Skye McGregor, Handan Wand, Hamish McManus, Amalie Dyda, Linda Garton, Belinda Hengel, Bronwyn J Silver, Debbie Taylor-Thomson, Janet Knox, Basil Donovan, Matthew Law, Lisa Maher, Christopher K Fairley, Steven Skov, Nathan Ryder, Elizabeth Moore, Jacqueline Mein, Carole Reeve, Donna Ah Chee, John Boffa and John M Kaldo

The Increased Length of Hospital Stay and Mortality Associated With Community-Associated Infections in Australia

Background: An increasing proportion of antibiotic-resistant infections are community acquired. However, the burden of community-associated infections (CAIs) and the resulting impact due to resistance have not been well described. Methods: We conducted a multisite, retrospective case-cohort study of all acute care hospital admissions across 134 hospitals in Australia. Patients admitted with a positive culture of 1 of 5 organisms of interest, namely Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecium, from January 1, 2012, through December 30, 2016, were included. Data linkage was used to link hospital admissions and pathology data. Patients with a bloodstream infection (BSI), urinary tract infection (UTI), or respiratory tract infection (RTI) were included in the analysis. We compared patients with a resistant and drug-sensitive infection and used regression analyses to derive the difference in length of hospital stay (LOS) and mortality estimates associated with resistance. Results: No statistically significant impact on hospital LOS for patients with resistant CAIs compared with drug-sensitive CAIs was identified. CAI patients with drug-resistant Enterobacteriaceae (E. coli, K. pneumoniae) BSIs were more likely to die in the hospital than those with drug-sensitive Enterobacteriaceae BSIs (odds ratio [OR], 3.28; 95% CI, 1.40-6.92). CAI patients with drug-resistant P. aeruginosa UTIs were more likely to die in the hospital than those with the drug-sensitive counterpart (OR,2.43; 95% CI, 1.12-4.85). Conclusions: The burden of CAI in the hospital is significant, and antibiotic resistance is adding to associated mortality.</p

Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea

MERS-CoV infection emerged in the Kingdom of Saudi Arabia (KSA) in 2012 and has spread to 26 countries. However, 80% of all cases have occurred in KSA. The largest outbreak outside KSA occurred in South Korea (SK) in 2015. In this report, we describe an epidemiological comparison of the two outbreaks. Data from 1299 cases in KSA (2012–2015) and 186 cases in SK (2015) were collected from publicly available resources, including FluTrackers, the World Health Organization (WHO) outbreak news and the Saudi MOH (MOH). Descriptive analysis, t-tests, Chi-square tests and binary logistic regression were conducted to compare demographic and other characteristics (comorbidity, contact history) of cases by nationality. Epidemic curves of the outbreaks were generated. The mean age of cases was 51 years in KSA and 54 years in SK. Older males (⩾70 years) were more likely to be infected or to die from MERS-CoV infection, and males exhibited increased rates of comorbidity in both countries. The epidemic pattern in KSA was more complex, with animal-to-human, human-to-human, nosocomial and unknown exposure, whereas the outbreak in SK was more clearly nosocomial. Of the 1186 MERS cases in KSA with reported risk factors, 158 (13.3%) cases were hospital associated compared with 175 (94.1%) in SK, and an increased proportion of cases with unknown exposure risk was found in KSA (710, 59.9%). In a globally connected world, travel is a risk factor for emerging infections, and health systems in all countries should implement better triage systems for potential imported cases of MERS-CoV to prevent large epidemics.Emerging Microbes & Infections (2017) 6, e51; doi:10.1038/emi.2017.40; published online 7 June 201

Epidemiology of Shiga toxin producing Escherichia coli in Australia, 2000-2010

Background: Shiga toxin-producing Escherichia coli (STEC) are an important cause of gastroenteritis in Australia and worldwide and can also result in serious sequelae such as haemolytic uraemic syndrome (HUS). In this paper we describe the epidemiology of STEC in Australia using the latest available data. Methods. National and state notifications data, as well as data on serotypes, hospitalizations, mortality and outbreaks were examined. Results: For the 11 year period 2000 to 2010, the overall annual Australian rate of all notified STEC illness was 0.4 cases per 100,000 per year. In total, there were 822 STEC infections notified in Australia over this period, with a low of 1 notification in the Australian Capital Territory (corresponding to a rate of 0.03 cases per 100,000/year) and a high of 413 notifications in South Australia (corresponding to a rate of 2.4 cases per 100,000/year), the state with the most comprehensive surveillance for STEC infection in the country. Nationally, 71.2% (504/708) of STEC infections underwent serotype testing between 2001 and 2009, and of these, 58.0% (225/388) were found to be O157 strains, with O111 (13.7%) and O26 (11.1%) strains also commonly associated with STEC infections. The notification rate for STEC O157 infections Australia wide between 2001-2009 was 0.12 cases per 100,000 per year. Over the same 9 year period there were 11 outbreaks caused by STEC, with these outbreaks generally being small in size and caused by a variety of serogroups. The overall annual rate of notified HUS in Australia between 2000 and 2010 was 0.07 cases per 100,000 per year. Both STEC infections and HUS cases showed a similar seasonal distribution, with a larger proportion of reported cases occurring in the summer months of December to February. Conclusions: STEC infections in Australia have remained fairly steady over the past 11 years. Overall, the incidence and burden of disease due to STEC and HUS in Australia appears comparable or lower than similar developed countries